Journal of Clinical Oncology
-
Publication Venue For
-
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer..
39:1165-1184.
2021
-
Next-Generation Endocrine Therapies for Breast Cancer..
JCO2003565.
2021
-
Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma..
39:807-821.
2021
-
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer..
39:723-733.
2021
-
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)..
39:822-835.
2021
-
Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer..
39:608-618.
2021
-
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline..
JCO2003399.
2021
-
Contemporary Multi-Institutional Cohort of 550 Cases of Phyllodes Tumors (2007-2017) Demonstrates a Need for More Individualized Margin Guidelines..
39:178-189.
2021
-
Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis..
39:136-144.
2021
-
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes..
38:4274-4282.
2020
-
Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group..
38:4194-4207.
2020
-
Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer..
38:3851-3862.
2020
-
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H..
38:3895-3904.
2020
-
Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient..
38:3773-3784.
2020
-
System for High-Intensity Evaluation During Radiation Therapy (SHIELD-RT): A Prospective Randomized Study of Machine Learning-Directed Clinical Evaluations During Radiation and Chemoradiation..
38:3652-3661.
2020
-
Volume Pledge is Not Associated with Better Short-Term Outcomes After Lung Cancer Resection..
38:3518-3527.
2020
-
Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study..
38:3418-3429.
2020
-
Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients..
38:3205-3216.
2020
-
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer..
38:3042-3050.
2020
-
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation..
38:3032-3041.
2020
-
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019..
38:2798-2811.
2020
-
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer..
JCO2001225.
2020
-
Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study..
38:2741-2752.
2020
-
Reply to J. Schildmann et al..
38:2815-2816.
2020
-
Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline..
38:2677-2694.
2020
-
Metastatic Pancreatic Cancer: ASCO Guideline Update..
JCO2001364.
2020
-
De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer..
38:2230-2239.
2020
-
Consistent Physical Activity and Future Neurocognitive Problems in Adult Survivors of Childhood Cancers: A Report From the Childhood Cancer Survivor Study..
38:2041-2052.
2020
-
Management of Male Breast Cancer: ASCO Guideline..
38:1849-1863.
2020
-
Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes..
38:1807-1813.
2020
-
Adherence to Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors: A Childhood Cancer Survivor Study..
38:1711-1722.
2020
-
State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach..
38:1633-1640.
2020
-
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)..
38:1539-1548.
2020
-
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease..
38:1273-1283.
2020
-
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance)..
38:1284-1292.
2020
-
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology..
38:1081.
2020
-
Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study..
38:1030-1040.
2020
-
Palliative and End-of-Life Care for Patients With Hematologic Malignancies..
38:944-953.
2020
-
Standards, Guidelines, and Quality Measures for Successful Specialty Palliative Care Integration Into Oncology: Current Approaches and Future Directions..
38:987-994.
2020
-
Assessing Patient-Reported Outcomes: A Negotiated Process..
38:652-653.
2020
-
Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331..
38:602-612.
2020
-
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study..
38:395-405.
2020
-
Prevalence and Predictors of Frailty in Childhood Cancer Survivors and Siblings: A Report From the Childhood Cancer Survivor Study..
38:232-247.
2020
-
Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma..
38:166-168.
2020
-
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study..
38:1-10.
2020
-
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer..
37:2974-2986.
2019
-
Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405..
37:2620-2631.
2019
-
Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653)..
37:2682-2688.
2019
-
Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study..
37:2556-2570.
2019
-
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial..
37:2338-2348.
2019
-
Reply to S. Sorscher..
37:2291-2293.
2019
-
Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study..
37:2131-2140.
2019
-
Reply to L. Dirix, B. De Laere et al, and A. Sharp et al..
37:2184-2186.
2019
-
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)..
37:1876-1885.
2019
-
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer..
37:1868-1875.
2019
-
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303..
37:1790-1799.
2019
-
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results..
37:1608-1616.
2019
-
Cognitive Implications of Ototoxicity in Pediatric Patients With Embryonal Brain Tumors..
37:1566-1575.
2019
-
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study..
37:1470-1478.
2019
-
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma..
37:1424-1431.
2019
-
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study..
37:1380-1390.
2019
-
Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial..
37:1326-1335.
2019
-
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome..
37:1217-1227.
2019
-
Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines..
37:1130-1135.
2019
-
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study..
37:1120-1129.
2019
-
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases..
37:1081-1089.
2019
-
Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study..
37:1090-1101.
2019
-
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers..
37:992-1000.
2019
-
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy..
37:693-702.
2019
-
Late Morbidity and Mortality Among Medulloblastoma Survivors Diagnosed Across Three Decades: A Report From the Childhood Cancer Survivor Study..
37:731-740.
2019
-
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial..
37:624-635.
2019
-
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial..
37:589-597.
2019
-
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel..
37:403-410.
2019
-
Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide..
37:367-374.
2019
-
Reply to A. Dalla Volta et al..
37:351-352.
2019
-
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors..
36:3298-3306.
2018
-
Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions..
JCO2018792309.
2018
-
Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline..
JCO1801097.
2018
-
Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048..
JCO2018788620.
2018
-
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study..
36:2492-2503.
2018
-
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update..
36:2545-2556.
2018
-
Minimally Invasive Lung Cancer Surgery Performed by Thoracic Surgeons as Effective as Thoracotomy..
36:2378-2385.
2018
-
Reply to J.J. Tao et al..
36:2451.
2018
-
Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology..
36:2326-2347.
2018
-
Models of Care for Survivors of Childhood Cancer From Across the Globe: Advancing Survivorship Care in the Next Decade..
36:2223-2230.
2018
-
Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review..
36:2145-2152.
2018
-
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu..
36:2044-2051.
2018
-
Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study..
36:1317-1322.
2018
-
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance)..
36:1112-1120.
2018
-
Reply to L. Fornaro et al..
36:1179-1180.
2018
-
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012..
36:991-999.
2018
-
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer..
36:773-779.
2018
-
Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update..
36:812-818.
2018
-
TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children..
36:591-599.
2018
-
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017..
36:414-424.
2018
-
Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer..
36:44-52.
2018
-
Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?.
35:3999-4002.
2017
-
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation..
35:4003-4011.
2017
-
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)..
35:3924-3933.
2017
-
Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors..
35:3837-3843.
2017
-
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)..
35:3671-3677.
2017
-
Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study..
35:3688-3696.
2017
-
Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial..
35:3714-3721.
2017
-
Financial Burden in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study..
35:3474-3481.
2017
-
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study..
35:3410-3416.
2017
-
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis..
35:3279-3289.
2017
-
The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer..
35:3175-3177.
2017
-
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer..
35:3097-3104.
2017
-
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies..
35:2885-2892.
2017
-
Immunotherapy for Brain Tumors..
35:2450-2456.
2017
-
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach..
35:2329-2337.
2017
-
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study..
35:2117-2124.
2017
-
Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care?.
35:2113-2116.
2017
-
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)..
35:2184-2192.
2017
-
Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update..
35:2082-2094.
2017
-
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database..
35:1929-1937.
2017
-
Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis..
35:1938-1944.
2017
-
Reply to J. Stenman et al..
35:1966-1967.
2017
-
United States Population-Based Estimates of Patient-Reported Outcomes Measurement Information System Symptom and Functional Status Reference Values for Individuals With Cancer..
35:1913-1920.
2017
-
Reply to B. Rini et al and S. Buti et al..
35:1859-1860.
2017
-
Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation..
35:1650-1659.
2017
-
Morbidity and Mortality Associated With Meningioma After Cranial Radiotherapy: A Report From the Childhood Cancer Survivor Study..
35:1570-1576.
2017
-
Is There a Role for Ovarian Cancer Screening in High-Risk Women?.
35:1384-1386.
2017
-
Reply to L. Casadaban et al..
35:1373-1374.
2017
-
Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry..
35:1162-1170.
2017
-
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes..
35:1154-1161.
2017
-
Reply to L.B. Marks et al..
35:1258-1259.
2017
-
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)..
35:1061-1069.
2017
-
Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma..
35:955-962.
2017
-
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline..
35:893-911.
2017
-
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial..
35:591-597.
2017
-
Reply to D.A. Palma..
35:572.
2017
-
Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527..
35:421-431.
2017
-
Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma..
35:208-216.
2017
-
Reply to A. Braillon, M. Boulin et al, and J.-H. Zhong et al..
35:258-259.
2017
-
Reply to M.A.N. Şendur et al and J. Michels..
35:123.
2017
-
Reply to T.-H. Wang et al..
35:118-120.
2017
-
Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems..
34:4415-4420.
2016
-
Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update..
34:4431-4442.
2016
-
Reply to J. Heil et al..
34:4192.
2016
-
Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012..
34:3992-3999.
2016
-
Longitudinal Changes in Depression Symptoms and Survival Among Patients With Lung Cancer: A National Cohort Assessment..
34:3984-3991.
2016
-
Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ..
34:4040-4046.
2016
-
Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy..
34:3576-3578.
2016
-
T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab..
34:3511-3517.
2016
-
How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer..
34:3434-3439.
2016
-
Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium..
34:3440-3450.
2016
-
Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study..
34:3240-3247.
2016
-
Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline..
34:3325-3345.
2016
-
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)..
34:3047-3053.
2016
-
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer..
34:2980-2987.
2016
-
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers..
34:2736-2742.
2016
-
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline..
34:2784-2796.
2016
-
Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline..
34:2654-2668.
2016
-
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis..
34:2468-2477.
2016
-
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013..
34:2359-2365.
2016
-
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer..
34:2325-2332.
2016
-
Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer..
34:2366-2371.
2016
-
Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care Among Medicare Beneficiaries With Stage IV Breast Cancer..
34:2265-2270.
2016
-
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study..
34:2258-2264.
2016
-
Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia..
34:2133-2140.
2016
-
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial..
34:2098-2106.
2016
-
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone..
34:2046-2053.
2016
-
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome..
34:1864-1871.
2016
-
Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer..
34:1732-1740.
2016
-
Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein..
34:1741-1747.
2016
-
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer..
34:1652-1659.
2016
-
Reply to N. Lowy et al and to J. Dhanda et al..
34:1708-1709.
2016
-
Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance)..
34:1484-1491.
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment..
34:1544-1557.
2016
-
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3..
34:1402-1418.
2016
-
Big Data, Small Effects..
34:1170-1171.
2016
-
Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study..
34:1122-1130.
2016
-
Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer..
34:1057-1064.
2016
-
Suicide: A Major Threat to Head and Neck Cancer Survivorship..
34:1151.
2016
-
Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study..
34:910-918.
2016
-
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases..
34:945-952.
2016
-
CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study..
34:863-870.
2016
-
Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907..
34:699-705.
2016
-
Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine..
34:e9-12.
2016
-
Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database..
34:144-150.
2016
-
Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer..
34:130-138.
2016
-
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502..
33:4167-4175.
2015
-
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed..
33:4039-4047.
2015
-
Enhancing Health Care of Survivors of Childhood Cancer With Tailored Education..
33:3849-3850.
2015
-
Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer..
33:3774-3780.
2015
-
Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement..
33:3826-3833.
2015
-
Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance)..
33:3598-3607.
2015
-
From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology..
33:3583-3590.
2015
-
Psychosocial Outcomes in Adult Survivors of Retinoblastoma..
33:3608-3614.
2015
-
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)..
33:3635-3640.
2015
-
Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses..
33:3130-3136.
2015
-
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update..
33:3199-3212.
2015
-
Intestinal Obstruction in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study..
33:2893-2900.
2015
-
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04..
33:2660-2666.
2015
-
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032..
33:2646-2654.
2015
-
Detecting Germline PTEN Mutations Among At-Risk Patients With Cancer: An Age- and Sex-Specific Cost-Effectiveness Analysis..
33:2537-2544.
2015
-
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial..
33:2450-2456.
2015
-
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)..
33:2384-2391.
2015
-
Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer..
33:2370-2375.
2015
-
Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial..
33:2231-2238.
2015
-
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance)..
33:1660-1665.
2015
-
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial..
33:1430-1437.
2015
-
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer..
33:1475-1481.
2015
-
C-reactive protein as a marker of melanoma progression..
33:1389-1396.
2015
-
Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis..
33:1379-1388.
2015
-
Making progress on progression in metastatic prostate cancer..
33:1322-1324.
2015
-
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer..
33:1325-1333.
2015
-
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia..
33:1252-1257.
2015
-
Different strokes for different folks: new paradigms for staging oropharynx cancer..
33:817-818.
2015
-
Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data..
33:567-574.
2015
-
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014..
33:654-656.
2015
-
Age-dependent changes in health status in the Childhood Cancer Survivor cohort..
33:479-491.
2015
-
Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review and meta-analysis..
33:501-509.
2015
-
Individual prediction of heart failure among childhood cancer survivors..
33:394-402.
2015
-
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database..
33:22-28.
2015
-
National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer..
32:4095-4101.
2014
-
Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance)..
32:3959-3966.
2014
-
Increasing cardiomyopathy screening in at-risk adult survivors of pediatric malignancies: a randomized controlled trial..
32:3974-3981.
2014
-
Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: a report from the childhood cancer survivor study..
32:3643-3650.
2014
-
Reply to F. Valcamonico et al..
32:3685.
2014
-
Early palliative care on an inpatient oncology unit: Impact of a novel co-rounding partnership on patient and health system outcomes..
32:3.
2014
-
Surgical interventions in cancer patients at the end of life: Experiences at an academic medical center..
32:281.
2014
-
There is a mismatch between the medicare benefit package and the preferences of patients with cancer and their caregivers..
32:3163-3168.
2014
-
Enhancing the efficacy of radiation therapy: premises, promises, and practicality..
32:2832-2835.
2014
-
Obesity and guideline-concordant systemic therapy for locoregional breast cancer..
32:145.
2014
-
Radical irradiation of extracranial oligometastases..
32:2902-2912.
2014
-
Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program..
32:2758-2764.
2014
-
In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma..
32:2705-2711.
2014
-
Breast and ovarian cancer in the older woman..
32:2553-2561.
2014
-
Breast and ovarian cancer in the older woman..
32:2553-2561.
2014
-
Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations..
32:2587-2594.
2014
-
Incorporating biomarkers into cancer and aging research..
32:2611-2616.
2014
-
New option for the initial management of metastatic pancreatic cancer?.
32:2405-2407.
2014
-
Results of the FFCD 9901 trial in early-stage esophageal carcinoma: is it really about neoadjuvant therapy?.
32:2398-2400.
2014
-
Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial..
32:2496-2502.
2014
-
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance)..
32:2311-2317.
2014
-
Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901..
32:2318-2327.
2014
-
Breast cancer after chest radiation therapy for childhood cancer..
32:2217-2223.
2014
-
Pain in cancer survivors..
32:1739-1747.
2014
-
Psychological and behavioral approaches to cancer pain management..
32:1703-1711.
2014
-
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial..
32:1563-1570.
2014
-
Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer..
32:1507-1515.
2014
-
Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study..
32:1218-1227.
2014
-
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905..
32:1242-1248.
2014
-
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)..
32:1143-1150.
2014
-
Reply to L.K. Mell et al..
32:1090-1091.
2014
-
Patient-reported quality of supportive care among patients with colorectal cancer in the Veterans Affairs Health Care System..
32:809-815.
2014
-
Reply to M.C. Chamberlain..
32:858-859.
2014
-
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer..
32:671-677.
2014
-
Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group..
32:527-534.
2014
-
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality..
32:273-281.
2014
-
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients..
32:114-120.
2014
-
Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline..
32:1502-1506.
2014
-
Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update..
32:1365-1383.
2014
-
American Society of Clinical Oncology 2013 top five list in oncology..
31:4362-4370.
2013
-
Reply to T.H. Oo..
31:4381-4382.
2013
-
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial..
31:4199-4206.
2013
-
Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis..
31:4188-4198.
2013
-
Comparison of QOPI measure conformance between oncology fellows and attending physicians..
31:162.
2013
-
Identifying benchmarks for ASCO's "Choosing Wisely" measures that address low-value imaging in early-stage prostate and breast cancer..
31:194.
2013
-
Prostate cancer and the hypofractionation hypothesis..
31:3849-3851.
2013
-
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy..
31:3944-3950.
2013
-
End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article..
31:3711-3718.
2013
-
Modifiable risk factors and major cardiac events among adult survivors of childhood cancer..
31:3673-3680.
2013
-
Examining potential colorectal cancer care disparities in the Veterans Affairs health care system..
31:3579-3584.
2013
-
Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study..
31:3494-3500.
2013
-
Patient experiences and preferences for survivorship care..
31:110.
2013
-
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)..
31:3061-3068.
2013
-
Time to define high-quality palliative care in oncology..
31:3047.
2013
-
High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031)..
31:2936-2941.
2013
-
Reply to S.P.Sura et al..
31:2512.
2013
-
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy..
31:2485-2492.
2013
-
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update..
31:2189-2204.
2013
-
Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581..
31:1775-1781.
2013
-
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer..
31:1740-1747.
2013
-
New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer..
31:1029-1038.
2013
-
Reply to M A Khattak et al..
31:972-973.
2013
-
A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed..
31:24.
2013
-
A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa)..
31:219.
2013
-
Image guidance for post-prostatectomy radiotherapy: Are we missing the mark?.
31:56.
2013
-
Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor..
31:6.
2013
-
Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial..
31:LBA8.
2013
-
Prognostic utility of CCP score in men with prostate cancer after primary external beam radiation therapy..
31:47.
2013
-
Relationship of oral glycine with radiation-induced HIF1-alpha and tumor growth delay in a prostate cancer xenograft..
31:81.
2013
-
Reply to M.S. Hofman et al..
31:820.
2013
-
American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care..
31:631-640.
2013
-
Appropriate design of prospective studies..
31:510-511.
2013
-
Influence of comorbidity on racial differences in receipt of surgery among US veterans with early-stage non-small-cell lung cancer..
31:475-481.
2013
-
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology..
31:131-161.
2013
-
Use of research biopsies in clinical trials: are risks and benefits adequately discussed?.
31:17-22.
2013
-
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia..
30:4515-4523.
2012
-
Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship..
30:4458-4461.
2012
-
Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation..
30:4427-4438.
2012
-
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin..
30:4344-4351.
2012
-
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?.
30:4396-4400.
2012
-
Comparative effectiveness research in oncology: an overview..
30:4181-4184.
2012
-
Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond..
30:4233-4242.
2012
-
Epilogue: the peril and the promise of comparative effectiveness research in oncology..
30:4282.
2012
-
Examining potential cancer care disparities in an equal access system: Quality of colorectal cancer care (CRC) in the Veterans Affairs (VA) health care system..
30:229.
2012
-
Impact of race on early-stage lung cancer treatment and survival..
30:232.
2012
-
Persistence of quality improvement in a Veterans Affairs (VA) academic practice assessed by Quality Oncology Practice Initiative (QOPI)..
30:209.
2012
-
Predictors of failure to perform pelvic peritoneal cytology in endometrial cancer staging surgery..
30:201.
2012
-
Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology..
30:4249-4255.
2012
-
The evolution of supportive care quality measures portfolio and conformance..
30:259.
2012
-
Parent-reported social outcomes after treatment for pediatric embryonal tumors: a prospective longitudinal study..
30:4134-4140.
2012
-
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101..
30:4071-4076.
2012
-
Unintended consequences of health information technology: evidence from veterans affairs colorectal cancer oncology watch intervention..
30:3947-3952.
2012
-
Ad5 immunity after multiple safe, homologous immunizations against tumor-associated antigens with new recombinant Ad5 vector..
30:85.
2012
-
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma..
30:3525-3532.
2012
-
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone..
30:3460-3467.
2012
-
Making genuine progress against metastatic breast cancer..
30:3448-3451.
2012
-
Pathologic complete response of a malignant peripheral nerve sheath tumor in the lung treated with neoadjuvant Ifosfamide and radiation therapy..
30:e291-e293.
2012
-
Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin..
30:3402-3407.
2012
-
Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children's Oncology Group study P9934..
30:3181-3186.
2012
-
American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology..
30:3136-3140.
2012
-
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures..
30:3109-3118.
2012
-
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline..
30:2912-2918.
2012
-
Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003..
30:2725-2730.
2012
-
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study..
30:2585-2592.
2012
-
Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901..
30:2609-2614.
2012
-
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer..
30:2615-2623.
2012
-
Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum..
30:2530-2537.
2012
-
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial..
30:2492-2499.
2012
-
Reach out to enhance wellness home-based diet-exercise intervention promotes reproducible and sustainable long-term improvements in health behaviors, body weight, and physical functioning in older, overweight/obese cancer survivors..
30:2354-2361.
2012
-
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer..
30:2218-2226.
2012
-
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial..
30:2063-2069.
2012
-
Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer..
30:2019-2020.
2012
-
Establishing a framework for improving the quality of clinical and translational research..
30:1725-1726.
2012
-
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group..
30:1415-1421.
2012
-
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline..
30:1553-1561.
2012
-
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401..
30:1534-1540.
2012
-
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers..
30:1321-1328.
2012
-
Prospective study of factors predicting adherence to surveillance mammography in women treated for breast cancer..
30:813-819.
2012
-
ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia..
30:751-757.
2012
-
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia..
30:742-750.
2012
-
Minimally invasive surgery for endometrial cancer: the horse is already out of the barn..
30:681-682.
2012
-
Design issues in randomized phase II/III trials..
30:667-671.
2012
-
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision..
30:600-607.
2012
-
Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?.
30:580-581.
2012
-
A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy..
30:97.
2012
-
A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy..
30:97.
2012
-
Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies..
30:435.
2012
-
Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies..
30:435.
2012
-
Awareness, concern, and communication between physicians and patients on bone health in nonmetastatic prostate cancer..
30:246.
2012
-
Awareness, concern, and communication between physicians and patients on bone health in nonmetastatic prostate cancer..
30:246.
2012
-
Colon cancer with microsatellite instability in a 13-year-old Hispanic male..
30:e55-e57.
2012
-
Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC)..
30:204.
2012
-
Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC)..
30:204.
2012
-
Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy..
30:129.
2012
-
Outcomes of "real world" treatment for metastatic renal cell carcinoma (mRCC)..
30:406.
2012
-
Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database..
30:34.
2012
-
Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database..
30:34.
2012
-
Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)..
30:200.
2012
-
The effect of acute and chronic exposure to acetaldehyde-a mutagenic metabolite of dietary ethanol-on prostate cancer cells: A potential source of race disparity disfavoring black men..
30:143.
2012
-
The effect of acute and chronic exposure to acetaldehyde-a mutagenic metabolite of dietary ethanol-on prostate cancer cells: A potential source of race disparity disfavoring black men..
30:143.
2012
-
Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)..
30:7.
2012
-
A novel interaction of genotype, gender, and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803..
30:452.
2012
-
A phase I/II study of capecitabine (Cape), oxaliplatin (Ox), panitumumab (Pmab), and external beam radiation therapy (RT) for patients with esophagogastric carcinoma (EC)..
30:68.
2012
-
Discovering pathways in the tumor microenvironment important for recurrence-free survival in patients with colorectal liver metastasis..
30:480.
2012
-
Patterns of failure following trimodality therapy for locally advanced esophageal cancer (EC)..
30:88.
2012
-
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors..
30:490.
2012
-
Predictive and prognostic markers of recurrence after resection of primary or metastatic colorectal cancer..
30:447.
2012
-
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases..
30:419-425.
2012
-
The effect of vascular reconstruction on early postoperative outcomes after pancreaticoduodenectomy: An analysis of the American College of Surgeons National Surgical Quality Improvement Program database..
30:153.
2012
-
Maximizing the efficacy of angiogenesis inhibitors..
30:337-338.
2012
-
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial..
30:268-273.
2012
-
Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study..
30:246-255.
2012
-
Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers..
30:142-150.
2012
-
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study..
29:4436-4441.
2011
-
Antiemetics: American Society of Clinical Oncology clinical practice guideline update..
29:4189-4198.
2011
-
DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy..
29:4121-4128.
2011
-
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer..
29:4022-4028.
2011
-
Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma..
29:3892-3899.
2011
-
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma..
29:e739-e742.
2011
-
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581..
29:3146-3152.
2011
-
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803..
29:3153-3162.
2011
-
Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407..
29:3120-3125.
2011
-
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression..
29:3037-3043.
2011
-
Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group..
29:3072-3077.
2011
-
Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma..
29:2918-2923.
2011
-
Fanconi's anemia in adulthood: chemoradiation-induced bone marrow failure and a novel FANCA mutation identified by targeted deep sequencing..
29:e591-e594.
2011
-
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma..
29:2787-2794.
2011
-
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer..
29:2598-2607.
2011
-
Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data..
29:2590-2597.
2011
-
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure..
29:2448-2458.
2011
-
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031..
29:2342-2349.
2011
-
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer..
29:2191-2198.
2011
-
A comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients..
29:e14026.
2011
-
A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study..
29:2533.
2011
-
A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED)..
29:2070.
2011
-
A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501)..
29:TPS223.
2011
-
A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC)..
29:5519.
2011
-
Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP)..
29:e15019.
2011
-
Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis..
29:7537.
2011
-
Allogeneic transplantation for patients with high-risk or refractory neuroblastoma..
29:9552.
2011
-
Assessment of clinical trials in oncology: An evaluation of 40,696 trials on ClinicalTrials.gov..
29:6095.
2011
-
Assessment of current practices among physicians and awareness and concern among patients for bone health in cancer..
29:e19617.
2011
-
Automated extraction of Quality Oncology Practice Initiative (QOPI) quality measures from the Veterans Health Administration (VHA) electronic health record system..
29:e16560.
2011
-
Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials..
29:2030.
2011
-
Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM)..
29:2098.
2011
-
Cigarette smoking is associated with advanced renal cell carcinoma..
29:2027-2031.
2011
-
Different risk factors for mortality in younger and older women after breast-conserving surgery..
29:6017.
2011
-
Does enrollment setting influence patient attributes and outcomes in RTOG prostate cancer trials?.
29:4607.
2011
-
Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC)..
29:4582.
2011
-
Financial implications of changes in the initial treatment of prostate cancer among Medicare beneficiaries..
29:6115.
2011
-
Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium..
29:4664.
2011
-
Modulation of angiogenic biomarkers in patients treated on a phase I study of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors..
29:10565.
2011
-
Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales-A report from the Children's Oncology Group (COG)..
29:9515.
2011
-
Outcomes in phase II trials of metastatic breast cancer: Where is the bar?.
29:2590.
2011
-
Pharmaceutical involvement in phase II breast cancer clinical trials..
29:6104.
2011
-
Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer..
29:3586.
2011
-
Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma..
29:2056.
2011
-
Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101..
29:4003.
2011
-
Predictors of pulmonary toxicity in limited-stage (LS) small cell lung cancer (SCLC) patients treated with concurrent chemotherapy (CTX) and high-dose (70 Gy) daily radiotherapy (RT): A pooled analysis of three CALGB studies..
29:7078.
2011
-
Prevalence and impact of correlative science in breast cancer phase II trials..
29:1046.
2011
-
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303..
29:10508.
2011
-
Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031..
29:7003.
2011
-
Quality appraisal of clinical validation studies for multigene prediction assays of chemotherapy response in early-stage breast cancer..
29:3082.
2011
-
Relationship between relative dose intensity and mortality in women receiving combination chemotherapy for stage III-IV epithelial ovarian cancer..
29:5084.
2011
-
Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT)..
29:10005.
2011
-
Role of the type III TGF-β receptor in modulating antitumor immunity during breast cancer progression..
29:10540.
2011
-
Safety and efficacy of single-agent adjuvant trastzumab in older women with breast cancer..
29:TPS109.
2011
-
Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma..
29:2082.
2011
-
Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls..
29:3557.
2011
-
Symptom experiences and nonadherent medication-taking behaviors of breast cancer patients taking adjuvant hormone therapy..
29:524.
2011
-
The role of biologic therapy in phase II breast cancer clinical trials..
29:e13048.
2011
-
Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma..
29:2055.
2011
-
Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581..
29:3518.
2011
-
Venous thromboembolic complications in patients with malignant glioma treated on a bevacizumab clinical trial..
29:9090.
2011
-
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies..
29:1757-1764.
2011
-
Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis..
29:1479-1487.
2011
-
Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1..
29:1472-1478.
2011
-
Assessment of quality of cancer-related follow-up care from the cancer survivor's perspective..
29:1280-1289.
2011
-
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401..
29:1290-1296.
2011
-
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study..
29:1373-1381.
2011
-
Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma..
29:1210-1215.
2011
-
Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907..
29:1022-1028.
2011
-
Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC)..
29:185.
2011
-
Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy..
29:118.
2011
-
Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC)..
29:189.
2011
-
Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups..
29:126.
2011
-
Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC)..
29:117.
2011
-
Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study..
29:825-831.
2011
-
Prognostic impact of post-prostatectomy PSA slope determined with a novel, nucleic acid detection immunoassay (NADiA ProsVue) for total PSA..
29:47.
2011
-
Prostate-specific antigen (PSA) progression-free survival (PFS): A comparison of degarelix versus leuprolide in patients with prostate cancer..
29:12.
2011
-
Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low- or intermediate-risk disease..
29:198.
2011
-
A phase I study of erlotinib, bevacizumab, and external beam radiation therapy (RT) for patients with localized pancreatic carcinoma (PC)..
29:281.
2011
-
Carcinoma of the ampulla of Vater: Patterns of failure after resection and benefit of adjuvant radiotherapy..
29:254.
2011
-
Development of an assay to predict oxaliplatin sensitivity from formalin-fixed, paraffin-embedded (FFPE) colorectal cancer tissues..
29:429.
2011
-
Multicenter evaluation of adjuvant therapy for gallbladder cancer..
29:251.
2011
-
Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer..
29:513.
2011
-
Quality of life after breast cancer diagnosis and survival..
29:406-412.
2011
-
Resected pancreatic neuroendocrine tumors: Patterns of failure and disease-related outcomes with or without radiotherapy..
29:325.
2011
-
Single-institution experience of preoperative chemoradiotherapy for locally advanced gastric cancer..
29:99.
2011
-
Use of gene expression profiling to determine prognosis and therapeutic targets for patients with appendiceal carcinoma..
29:418.
2011
-
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study..
29:294-302.
2011
-
Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?.
29:e18-e20.
2011
-
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials..
29:83-88.
2011
-
Progressive multifocal leukoencephalopathy with occult Waldenström macroglobulinemia..
28:e759-e761.
2010
-
Availability of experimental therapy outside oncology randomized clinical trials in the United States..
28:5067-5073.
2010
-
Clinical trials data collection: when less is more..
28:5019-5021.
2010
-
Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11..
28:5061-5066.
2010
-
Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications..
28:5046-5053.
2010
-
American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer..
28:4996-5010.
2010
-
Bevacizumab and everolimus in renal cancer: a rational way forward..
28:e692-e693.
2010
-
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma..
28:4722-4729.
2010
-
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma..
28:4521-4530.
2010
-
Long-term efficacy of methylphenidate in enhancing attention regulation, social skills, and academic abilities of childhood cancer survivors..
28:4465-4472.
2010
-
Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803..
28:4354-4363.
2010
-
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study..
28:4207-4213.
2010
-
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure..
28:3730-3738.
2010
-
Economic implications of 21-gene recurrence score assay: US multicenter experience..
28:e382.
2010
-
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)..
28:3617-3622.
2010
-
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205..
28:3605-3610.
2010
-
Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials..
28:3416-3421.
2010
-
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer..
28:3336-3343.
2010
-
Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians..
28:3146-3153.
2010
-
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study..
28:3191-3198.
2010
-
Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs..
28:3176-3181.
2010
-
A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401..
28:LBA4511.
2010
-
Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas..
28:3048-3053.
2010
-
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study..
28:3069-3075.
2010
-
Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review..
28:2914-2924.
2010
-
Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104..
28:2418-2422.
2010
-
Development of a multimarker assay for early detection of ovarian cancer..
28:2159-2166.
2010
-
Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome..
28:2198-2206.
2010
-
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer..
28:2181-2190.
2010
-
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206..
28:2137-2143.
2010
-
Optimal lesion number for evaluation of tumor response in response evaluation criteria in solid tumors..
28:e159-e160.
2010
-
Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial..
28:1395-1400.
2010
-
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer..
28:1124-1130.
2010
-
Seduced by dose?.
28:1087-1089.
2010
-
Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer..
28:620-627.
2010
-
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors..
28:549-555.
2010
-
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance..
28:453-459.
2010
-
Hodgkin's lymphoma of the breast..
28:e11-e13.
2010
-
Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904..
28:202-206.
2010
-
Predictors of competing mortality in advanced head and neck cancer..
28:15-20.
2010
-
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909..
27:6101-6108.
2009
-
Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer..
27:5838-5847.
2009
-
Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia..
27:5580-5586.
2009
-
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment..
27:5660-5669.
2009
-
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904..
27:5506-5512.
2009
-
Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review..
27:5476-5486.
2009
-
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial..
27:5431-5438.
2009
-
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen..
27:5208-5212.
2009
-
Cancer, clots and consensus: new understanding of an old problem..
27:4821-4826.
2009
-
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival..
27:4902-4911.
2009
-
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action..
27:4919-4926.
2009
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma..
27:4733-4740.
2009
-
Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024..
27:4727-4732.
2009
-
Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402..
27:4487-4491.
2009
-
Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma..
27:4197-4203.
2009
-
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411..
27:4096-4102.
2009
-
Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia..
27:3698-3704.
2009
-
Adjuvant hormonal therapy use among insured, low-income women with breast cancer..
27:3445-3451.
2009
-
Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy..
27:3370-3378.
2009
-
Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206..
27:LBA5019.
2009
-
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study..
27:3020-3026.
2009
-
Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis..
27:2831-2837.
2009
-
Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia..
27:2838-2847.
2009
-
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer..
27:2766-2771.
2009
-
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater..
27:2598-2603.
2009
-
A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors..
27:e15506.
2009
-
A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma..
27:e13024.
2009
-
Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors..
27:3551.
2009
-
Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC)..
27:4080.
2009
-
Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206..
27:LBA5019.
2009
-
Can primary recurrences in surgical stage I-II uterine papillary serous carcinoma (UPSC) patients be salvaged?.
27:e16503.
2009
-
Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma..
27:11001.
2009
-
Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801..
27:7535.
2009
-
Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry..
27:5131.
2009
-
Correlation of body mass index with toxicity and survival in locoregionally advanced head and neck cancer patients treated with induction chemotherapy and concurrent chemoradiotherapy..
27:6074.
2009
-
Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial..
27:5150.
2009
-
Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086)..
27:5061.
2009
-
Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens..
27:5137.
2009
-
Dual inhibition of αV integrins and Src kinase activity in colon cancer cells..
27:e14609.
2009
-
Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM..
27:2034.
2009
-
Effect of treatment of patients with early-stage uterine carcinosarcoma..
27:5516.
2009
-
Electronic patient-reported data capture as the foundation of a learning health care system..
27:6522.
2009
-
Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM..
27:2021.
2009
-
Factors associated with chemotherapy receipt and intensity for stage IV colorectal cancer (CRC): A multihealth system, population-based study..
27:6519.
2009
-
Impact of a psychosocial intervention on performance status and coping..
27:9611.
2009
-
Implementation of genomic predictors of chemotherapy response for guiding preoperative therapy in a prospective breast cancer trial..
27:11057.
2009
-
KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803..
27:4037.
2009
-
Measurement of gene expression biomarkers by qNPA from archived NSCLC FFPE: Prognosis of 5-year survival..
27:11098.
2009
-
Multiagent concurrent chemoradiotherapy (MACCRT) and gefitinib in locoregionally advanced head and neck squamous cell cancer (HNSCC)..
27:6037.
2009
-
Neurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN study..
27:2056.
2009
-
Novel organic arsenic molecule darinaparsin: Development of IV and oral forms..
27:8501.
2009
-
Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma..
27:e13007.
2009
-
Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas..
27:e13016.
2009
-
Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas..
27:2045.
2009
-
Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581..
27:4012.
2009
-
Prognostic significance of early changes in the apparent diffusion coefficient that occurs after treatment of patients with glioblastoma multiforme with bevacizumab..
27:2058.
2009
-
Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM)..
27:2015.
2009
-
Survivorship care planning needs in diffuse large B-cell lymphoma (DLBCL)..
27:e20703.
2009
-
Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM)..
27:e13025.
2009
-
The relationship between adherence to adjuvant hormonal therapy and survival among low-income, insured women with primary breast cancer..
27:e11522.
2009
-
Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial..
27:5148.
2009
-
Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings..
27:2339-2355.
2009
-
Health behaviors, medical care, and interventions to promote healthy living in the Childhood Cancer Survivor Study cohort..
27:2363-2373.
2009
-
High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance..
27:2405-2414.
2009
-
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment..
27:2185-2191.
2009
-
Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114)..
27:1956-1962.
2009
-
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803..
27:1814-1821.
2009
-
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301..
27:1800-1805.
2009
-
Hidden biases in an observational study of bevacizumab beyond progression..
27:1732-1733.
2009
-
Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer..
27:1592-1599.
2009
-
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma..
27:1262-1267.
2009
-
US intergroup anal carcinoma trial: tumor diameter predicts for colostomy..
27:1116-1121.
2009
-
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma..
27:843-850.
2009
-
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma..
27:433-438.
2009
-
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials..
27:199-205.
2009
-
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704..
26:5918-5922.
2008
-
Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group..
26:5797-5801.
2008
-
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206..
26:5422-5428.
2008
-
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group..
26:5360-5367.
2008
-
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases..
26:5344-5351.
2008
-
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups..
26:5043-5051.
2008
-
Defining best supportive care..
26:5139-5140.
2008
-
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720..
26:4934-4939.
2008
-
Association between hepatitis B virus and pancreatic cancer..
26:4557-4562.
2008
-
Does computed tomography or positron emission tomography response after neoadjuvant chemotherapy for resectable non-small-cell lung cancer predict survival?.
26:4542-4543.
2008
-
Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study..
26:4639-4645.
2008
-
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113..
26:4551-4556.
2008
-
Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma..
26:4511-4513.
2008
-
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer..
26:4418-4425.
2008
-
Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study..
26:4401-4409.
2008
-
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation..
26:4442-4448.
2008
-
Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study..
26:4144-4150.
2008
-
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803..
26:4109-4115.
2008
-
Patient education level as a predictor of survival in lung cancer clinical trials..
26:4116-4123.
2008
-
American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges..
26:4022-4026.
2008
-
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma..
26:3749-3755.
2008
-
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma..
26:3743-3748.
2008
-
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head..
26:3487-3495.
2008
-
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head..
26:3496-3502.
2008
-
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression..
26:3324-3330.
2008
-
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281)..
26:3229-3234.
2008
-
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer..
26:3213-3221.
2008
-
Erythropoiesis-stimulating agents in cancer..
26:3097-3098.
2008
-
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B..
26:2659-2665.
2008
-
A genomic approach to identify therapeutic targets in histologic subtypes of soft tissue sarcoma..
26:10577.
2008
-
A phase I study of Iobenguane I 131 to evaluate MTD, efficacy and safety in patients with malignant pheochromocytoma/paraganglioma (Pheo)..
26:4605.
2008
-
A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer..
26:1099.
2008
-
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603..
26:4515.
2008
-
A prospective multicenter study of guanylyl cyclase C (GCC), quantified by the reverse transcriptase-polymerase chain reaction (qRT-PCR), as a prognostic marker of occult metastases in lymph nodes of pN0 colorectal cancer patients..
26:11011.
2008
-
A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children's Oncology Group study..
26:10011.
2008
-
Comparison of the biology of Down syndrome (DS) acute lymphoblastic leukemia (ALL) and non-DS ALL: Children's Oncology Group (COG) study P9900..
26:10003.
2008
-
Depletion of human regulatory T cells (Treg) and antigen-specific immune responses to cancer vaccines..
26:3010.
2008
-
E/Tablets to collect research-quality, patient-reported data..
26:17528.
2008
-
Factors influencing outcome after pulmonary resection for colorectal cancer (CRC) metastases in the current era..
26:4024.
2008
-
Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG)..
26:2057.
2008
-
Gene expression determinants of ovarian cancer platinum-response in older women..
26:22059.
2008
-
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma..
26:9077.
2008
-
Genomic-based signatures of chemosensitivity and ER/HER2 status in biologic replicate breast cancer samples..
26:11068.
2008
-
Improving quality at university based hematology/oncology fellowship continuity clinic with the quality oncology practice initiative (QOPI)..
26:6578.
2008
-
Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients..
26:8057.
2008
-
Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC)..
26:4063.
2008
-
Integration of clinico-pathologic variables, mRNA, and microRNA profiles represents an optimal strategy to predict sensitivity to chemotherapeutic agents in breast cancer..
26:14567.
2008
-
Ki67 and PIM1 expression in aggressively treated mantle cell lymphoma (MCL): A Cancer and Leukemia Group B (CALGB) 59909 correlative science study..
26:8560.
2008
-
LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: Results of CALGB 80402..
26:4109.
2008
-
Local/regional recurrence following surgery for early-stage lung cancer: A 10-year experience with 975 patients..
26:7542.
2008
-
Longitudinal patterns of chemotherapy (CT) use in metastatic colorectal cancer (mCRC)..
26:15082.
2008
-
Mortality burden of melanoma: Metastatic site-specific and temporal trends..
26:9076.
2008
-
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer..
26:2544-2549.
2008
-
Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma..
26:4604.
2008
-
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma..
26:2489-2496.
2008
-
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105..
26:2457-2463.
2008
-
The actuarial incidence of brain metastases in 975 patients undergoing surgery for early-stage lung cancer..
26:8094.
2008
-
The association between RT-induced changes in lung density and global lung function..
26:13543.
2008
-
The efficacy and tolerability of transarterial chemo-embolization (TACE) compared with transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (HCC)..
26:4595.
2008
-
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from intergroup trial CALGB 89803..
26:4039.
2008
-
The patient reported outcomes measurement information system-Cancer (PROMIS-Ca): Cancer-specific application of a generic fatigue measure..
26:6537.
2008
-
The relationship between LHRH-agonist depot formulations and frequency of follow-up with health care providers in patients with prostate cancer..
26:16002.
2008
-
Transcription factors Stat5a and Stat5b: Favorable prognostic markers in breast cancer..
26:22071.
2008
-
Treatment-related toxicity and supportive care in metastatic colorectal cancer (mCRC)..
26:15087.
2008
-
Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2-8, and PAX9, to predict prognosis and guide therapeutic strategies..
26:7511.
2008
-
Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group..
26:2390-3295.
2008
-
Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study..
26:2186-2191.
2008
-
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer..
26:1993-1999.
2008
-
Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway..
26:2000-2005.
2008
-
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840..
26:1642-1649.
2008
-
Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials..
26:1400-1401.
2008
-
Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database..
26:1483-1488.
2008
-
Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma..
26:1459-1464.
2008
-
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b..
26:1316-1323.
2008
-
Bilateral panocular involvement with mantle-cell lymphoma..
26:1167.
2008
-
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group..
26:1148-1159.
2008
-
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy..
26:1066-1072.
2008
-
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781..
26:1086-1092.
2008
-
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203..
26:848-855.
2008
-
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103..
26:870-876.
2008
-
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials..
26:527-534.
2008
-
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107..
26:183-189.
2008
-
Stemming the tide of hepatitis B virus related hepatocellular carcinoma?.
26:172-174.
2008
-
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan..
26:271-278.
2008
-
Oncologist communication about emotion during visits with patients with advanced cancer..
25:5748-5752.
2007
-
Panel of serum biomarkers for the diagnosis of lung cancer..
25:5578-5583.
2007
-
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer..
25:5490-5505.
2007
-
Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative..
25:5106-5112.
2007
-
Randomized clinical trial design for assessing noninferiority when superiority is expected..
25:5019-5023.
2007
-
Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study..
25:4993-4997.
2007
-
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme..
25:4722-4729.
2007
-
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy..
25:4793-4799.
2007
-
Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience..
25:4581-4586.
2007
-
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study..
25:4557-4561.
2007
-
Using prospect theory to understand end-of-life decisions..
25:4700.
2007
-
Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer..
25:4350-4357.
2007
-
Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer..
25:4405-4413.
2007
-
Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers..
25:4033-4042.
2007
-
Chemoradiotherapy for locally advanced head and neck cancer..
25:4118-4126.
2007
-
Pharmacologic approaches to radiation protection..
25:4084-4089.
2007
-
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer..
25:3965-3970.
2007
-
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer..
25:3719-3725.
2007
-
Chemotherapy administration for ovarian cancer by gynecologic oncologists and medical oncologists..
25:3552.
2007
-
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803..
25:3456-3461.
2007
-
The fallacy of single-agent chemotherapy for cancer..
25:3550.
2007
-
Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas..
25:3321-3329.
2007
-
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review..
25:3158-3167.
2007
-
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101..
25:3055-3060.
2007
-
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma..
25:3109-3115.
2007
-
Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors..
25:2709-2718.
2007
-
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer..
25:2811-2818.
2007
-
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens..
25:2522-2527.
2007
-
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma..
25:2464-2472.
2007
-
The cancer aging interface: a research agenda..
25:1945-1948.
2007
-
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B..
25:1698-1704.
2007
-
Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma..
25:1350-1356.
2007
-
Erythropoietin: high profile, high scrutiny..
25:1021-1023.
2007
-
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma..
25:1054-1060.
2007
-
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia..
25:1114-1120.
2007
-
Intraoperative radiation therapy..
25:971-977.
2007
-
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group..
25:837-844.
2007
-
Ductal carcinoma in situ in BRCA mutation carriers..
25:642-647.
2007
-
Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution..
25:690-697.
2007
-
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy..
25:277-284.
2007
-
Value of high-cost cancer care: a behavioral science perspective..
25:223-227.
2007
-
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia..
25:25-31.
2007
-
Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study..
24:5277-5282.
2006
-
Models for delivering survivorship care..
24:5117-5124.
2006
-
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer..
24:5025-5033.
2006
-
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127..
24:4922-4927.
2006
-
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes..
24:4642-4660.
2006
-
Genomic prediction of locoregional recurrence after mastectomy in breast cancer..
24:4594-4602.
2006
-
Magnetic resonance imaging captures the biology of ductal carcinoma in situ..
24:4603-4610.
2006
-
Problems with the randomized discontinuation design..
24:4669-4670.
2006
-
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B..
24:4553-4557.
2006
-
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer..
24:4441-4447.
2006
-
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020..
24:4196-4201.
2006
-
Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response..
24:3953-3958.
2006
-
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803..
24:3535-3541.
2006
-
Lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from Project LEAD..
24:3465-3473.
2006
-
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline..
24:3187-3205.
2006
-
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole..
24:3019-3025.
2006
-
A comparison of combination docetaxel/carboplatin versus sequential docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer..
24:5092.
2006
-
A genomic strategy to combinatorial therapeutics in solid tumors..
24:2031.
2006
-
A genomic strategy to refine prognosis in early stage non-small cell lung carcinoma (NSCLC)..
24:7026.
2006
-
A lung cancer genomic risk prediction model derived from paraffin-embedded tissue..
24:10059.
2006
-
A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer..
24:5019.
2006
-
A novel low molecular weight inhibitor of focal adhesion kinase and insulin-like growth factor-1 receptor, TAE226, inhibits glioma growth..
24:11505.
2006
-
A novel role of DNA fragmentation factor as a tumor suppressor through maintaining genomic stability..
24:10023.
2006
-
A phase I study of capecitabine (CAP), carboplatin (CARB), paclitaxel (TAX) and external beam radiation therapy (EBRT) for patients with esophageal carcinoma (EC)..
24:14044.
2006
-
A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma..
24:1580.
2006
-
A phase II study of bortezomib in relapsed Hodgkin lymphoma: Preliminary results of CALGB 50206..
24:7576.
2006
-
A phase II study of temozolomide and oral VP-16 for adults with recurrent glioma-Final results..
24:1565.
2006
-
Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma..
24:11504.
2006
-
Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633..
24:7007.
2006
-
An elevated body mass (BMI) index predicts for better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC)..
24:4556.
2006
-
An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma..
24:1560.
2006
-
Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas..
24:1506.
2006
-
CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC)..
24:4582.
2006
-
Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide: Study of cases..
24:11522.
2006
-
Differential canonical pathways derived from microarrays using RNA from paraffin-embedded non-small cell lung cancer tissue..
24:7226.
2006
-
Does positron emission tomography (PET) improve our ability to detect residual neck node (NN) disease in patients with squamous cell head and neck cancer (SCHNC) after definitive chemoradiotherapy?.
24:5526.
2006
-
Ex vivo activation and expansion of γδ T cells for immunotherapy of glioblastoma..
24:2553.
2006
-
High expression of nucleoside transporter hENT1 predicts a worse event-free survival in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin-A CALGB 59804 correlative study..
24:7581.
2006
-
Lessons learned from two decades of sentinel node biopsies for melanoma..
24:8055.
2006
-
Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782..
24:4573.
2006
-
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer..
24:10003.
2006
-
Oral mucositis (OM) related morbidity and resource utilization in a prospective study of head and neck cancer (HNC) patients..
24:5539.
2006
-
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck..
24:2866-2872.
2006
-
Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102..
24:4578.
2006
-
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104..
24:8014.
2006
-
Phase II trial of Gliadel plus O(6)-benzylguanine (O(6)-BG) for patients with recurrent glioblastoma multiforme..
24:1568.
2006
-
Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas..
24:1573.
2006
-
Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results..
24:3509.
2006
-
Prognostic significance of children with cutaneous melanoma: Implications for treatment..
24:8021.
2006
-
Quality measures for the diagnosis and management of colorectal cancer..
24:16031.
2006
-
Race/ethnicity, literacy, and prostate cancer: Initial findings from the COMPARE registry..
24:4620.
2006
-
Relationship between numeracy and breast cancer patients' estimates of adjuvant treatment benefit..
24:586.
2006
-
Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781..
24:4012.
2006
-
Tinzaparin prophylaxis against thromboembolic complications in brain tumor patients..
24:1539.
2006
-
Tumor-specific peptide vaccination in newly-diagnosed patients with GBM..
24:2529.
2006
-
Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum..
24:2612-2617.
2006
-
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901..
24:2557-2562.
2006
-
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes..
24:2456-2464.
2006
-
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma..
24:2505-2512.
2006
-
Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer..
24:1720-1728.
2006
-
Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation..
24:1627-1632.
2006
-
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy..
24:1449-1453.
2006
-
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)..
24:1395-1403.
2006
-
Recent advances in the treatment of malignant astrocytoma..
24:1253-1265.
2006
-
Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution..
24:1064-1071.
2006
-
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer..
24:1145-1151.
2006
-
Withholding antibiotics from patients with febrile neutropenia..
24:1221-1222.
2006
-
Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001..
24:878-883.
2006
-
Characterization of BRCA1 and BRCA2 mutations in a large United States sample..
24:863-871.
2006
-
Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications..
24:605-611.
2006
-
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results..
24:656-662.
2006
-
Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012..
24:650-655.
2006
-
Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B..
24:407-412.
2006
-
Thromboembolism in hospitalized neutropenic cancer patients..
24:484-490.
2006
-
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer..
24:217-227.
2006
-
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma..
24:16-24.
2006
-
Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months..
24:145-151.
2006
-
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results..
24:115-122.
2006
-
Correlation of clinical outcome with natural killer (NK) response to an anti-cancer, dendritic cell-based vaccine..
23:2585.
2005
-
Expression analysis of genes involved in ovarian cancer metastasis..
23:5038.
2005
-
Expression of phosphorylated epidermal growth factor receptor (p-EGFR) in early stage non-small cell lung cancer: its relationship with overexpression of EGFR and cyclooxygenase-2 (COX-2), and survival..
23:9614.
2005
-
Gene expression signatures for prognosis in NSCLC, coupled with signatures of oncogenic pathway deregulation, provide a novel approach for selection of molecular targets..
23:7020.
2005
-
High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial..
23:7543.
2005
-
Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803..
23:3530.
2005
-
Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103..
23:6530.
2005
-
Predictors of prostate cancer-specific mortality following radical prostatectomy or radiation therapy..
23:4548.
2005
-
Results of Project LEAD (Leading the Way in Exercise and Diet) - A trial testing an intervention of telephone-counseling and mailed materials in improving physical functioning among older breast and prostate cancer survivors..
23:8138.
2005
-
The impact of physical activity on patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803..
23:3534.
2005
-
Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: Preliminary safety and immunogenicity results from a phase 1 trial..
23:2571.
2005
-
A phase 2 trial of high-dose Allovectin-7 in patients with advanced metastatic melanoma..
22:7509.
2004
-
A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients..
22:2525.
2004
-
A phase I/II study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901..
22:3560.
2004
-
A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008..
22:4515.
2004
-
A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904)..
22:4011.
2004
-
A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials..
22:4506.
2004
-
Effect of zoledronic acid on clinically meaningful changes in pain associated with metastatic prostate cancer..
22:4680.
2004
-
Efficacy of peripheral androgen blockade on prostate cancer: Results of CALGB 9782..
22:4559.
2004
-
Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial..
22:1555.
2004
-
Erythropoietin (EPO) has no direct effect on tumor growth or angiogenesis in animal models..
22:9530.
2004
-
Fulfillment of the uncertainty principle in cancer clinical trials..
22:6003.
2004
-
Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial..
22:7005.
2004
-
Intraperitoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma..
22:5038.
2004
-
Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803)..
22:3500.
2004
-
Is the second primary malignancy an important competing cause of death in patients (pts) with squamous cell head and neck cancer (SCHNC)?.
22:5516.
2004
-
Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer: Toxicity and outcome results..
22:5561.
2004
-
Phase I study of immunization with dendritic cells (DC) modified with recombinant fowlpox encoding carcinoembryonic antigen (CEA) and the triad of costimulatory molecules CD54, CD58, and CD80 (rF-CEA(6D)-TRICOM) in patients with advanced malignancies..
22:2508.
2004
-
Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer..
22:5152.
2004
-
Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer..
22:5089.
2004
-
Phase II study of thalidomide and daily cyclophosphamide for adults with malignant glioma..
22:1554.
2004
-
Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102..
22:4540.
2004
-
Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors..
22:1569.
2004
-
Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581)..
22:3522.
2004
-
Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480..
22:4557.
2004
-
RARbeta P2 promoter methylation: Potential biomarker for use with breast Random Periareolar Fine Needle Aspiration in breast cancer risk assessment..
22:1014.
2004
-
Regulatory and effector T cell subsets and dendritic cells in breast cancer..
22:9697.
2004
-
Safety profile of therapeutic pox virus-based vaccines for cancer..
22:2513.
2004
-
Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480..
22:9613.
2004
-
Sentinel node staging of resectable colon cancer: Results of CALGB 80001..
22:3506.
2004
-
The effect of race on progression-free survival in patients with metastatic hormone-refractory prostate cancer (HRPC): a pooled analysis of CALGB studies..
22:4573.
2004
-
The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: Two year follow-up of a prospective randomized trial..
22:5536.
2004
-
Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: Results from CALGB 9583..
22:4558.
2004
-
Utility of end consolidation bone marrow aspirates in childhood acute lymphoblastic leukemia [ALL]: A Pediatric Oncology Group study [POG]..
22:8564.
2004
-
Retraction. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer..
30:678.
2012
-
Retraction. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25:4350–7, 2007..
28:5229.
2010
-
An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer..
25:517-525.
2007
-
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
2021
-
Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
2019
-
Late Infection-Related Mortality in Asplenic Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
2018
-
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
2018
-
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
2017
-
Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy.
2016
-
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
2016
-
Patient-Reported Outcomes After Choice for Contralateral Prophylactic Mastectomy.
2016
-
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
2014
-
Health-related quality of life and symptom management research sponsored by the National Cancer Institute.
2007
-
Patient-reported outcomes assessment in cancer trials: evaluating and enhancing the payoff to decision making.
2007
-
Patient-reported outcomes assessment in cancer trials: taking stock, moving forward.
2007
-
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
2006